Sanofi stock up on Pfizer buyout talk

Sanofi-Aventis stock spiked this morning after rumors of a Pfizer buyout sparked a flurry of trading. The oil company Total does own 13 percent of Sanofi, and it has been looking to offload those shares. Pfizer was rumored to have approached Total four years ago, but that was before the Aventis merger boosted Sanofi's market cap to some $121 billion.

The rationale: Pfizer would buy Total's shares and use them as a foot in the door to an eventual buyout. L'Oreal owns another ten percent, and though it has said it's not interested in selling, that doesn't quell takeover talk. Neither Sanofi nor Pfizer would comment.

- read the report from Lab Technologist
- see this Pharmalot item

Related Articles:
Pfizer, Wyeth merger bad idea? Report
Wyeth buyout a good deal for Pfizer? Report
Sanofi underscores pipeline advances, setbacks. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.